Sodium zirconium cyclosilicate
Sodium zirconium cyclosilicate is a pharmaceutical drug with 15 clinical trials. Currently 4 active trials ongoing. Historical success rate of 63.6%.
Success Metrics
Based on 7 completed trials
Phase Distribution
Phase Distribution
1
Early Stage
3
Mid Stage
11
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
63.6%
7 of 11 finished
36.4%
4 ended early
4
trials recruiting
15
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Comparison of Potassium Binders in the ER
A Clinical Trial to Define the Best Strategy for the Management of Heart Failure in Elderly Patients
Study to Assess Efficacy and Safety of SZC for the Management of High Potassium in Patients With Symptomatic HFrEF Receiving Spironolactone
OPtimizing Aldosterone Receptor Antagonist Therapy by Sodium Zirconium Cyclosilicate in Heart Failure
The ORTIZ Study: Optimising RASi Therapy With SZC
Clinical Trials (15)
Comparison of Potassium Binders in the ER
A Clinical Trial to Define the Best Strategy for the Management of Heart Failure in Elderly Patients
Study to Assess Efficacy and Safety of SZC for the Management of High Potassium in Patients With Symptomatic HFrEF Receiving Spironolactone
OPtimizing Aldosterone Receptor Antagonist Therapy by Sodium Zirconium Cyclosilicate in Heart Failure
The ORTIZ Study: Optimising RASi Therapy With SZC
Sodium Zirconium Cyclosilicate to Allow Liberal Fruit and Vegetable Intake for Patients With CKD Stage 3b and 4
Keeping RAASi Treatment With Optimal Potassium Control
Study to Assess the Effect of Sodium Zirconium Cyclosilicate on the Pharmacokinetics of Tacrolimus and Cyclosporin in Healthy Subjects
Study of the Effect of SZC on Serum Potassium and Serum Bicarbonate in Patients With Hyperkalemia and Metabolic Acidosis Associated With Chronic Kidney Disease
Reduce Incidence of Pre-Dialysis Hyperkalaemia With Sodium Zirconium Cyclosilicate in Chinese Subjects
Sodium Zirconium Cyclosilicate Lowers Hyperkalemia After Parathyroidectomy
Potassium Reduction Initiative to Optimize RAAS Inhibition Therapy With Sodium Zirconium Cyclosilicate in Heart Failure
Safety & Efficacy of Zirconium Silicate Dosed for 28 Days in Hyperkalemia.
Open-label Safety & Efficacy of ZS (Sodium Zirconium Cyclosilicate)10g qd to Extend Study ZS-004 in Hyperkalemia.
Open-label Safety and Efficacy of Sodium Zirconium Cyclosilicate for up to 12 Months
All 15 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 15